Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May 4;212(5):601-5.
doi: 10.1084/jem.20150656.

Precision medicine: Clarity for the clinical and biological complexity of Alzheimer's and Parkinson's diseases

Thomas J Montine  1 , Kathleen S Montine  1
Affiliations
Review

Precision medicine: Clarity for the clinical and biological complexity of Alzheimer's and Parkinson's diseases

Thomas J Montine et al. J Exp Med. .

Abstract

The goal of precision medicine is to deliver optimally targeted and timed interventions tailored to an individual's molecular drivers of disease. This concept has wide currency in cancer care and in some diseases caused by monogenetic mutations, such as cystic fibrosis, and recently has been endorsed by the White House Office of Science and Technology for more widespread application in medicine. Here we describe our vision of how precision medicine can bring greater clarity to the clinical and biological complexity of the two most common neurodegenerative diseases, Alzheimer's disease and Parkinson's disease.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Three key elements of precision medicine for AD and PD. We envision an approach that begins with (1) comprehensive risk assessment to identify underlying factors, (2) utilizes tools for preclinical detection of pathophysiologic processes, and leads to (3) molecularly tailored interventions. Blue, green, and gray represent different risk groups.
See this image and copyright information in PMC

References

    1. Aarsland D., Andersen K., Larsen J.P., Lolk A., and Kragh-Sørensen P.. 2003. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60:387–392 10.1001/archneur.60.3.387 - DOI - PubMed
    1. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., et al. . 2011. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7:270–279 10.1016/j.jalz.2011.03.008 - DOI - PMC - PubMed
    1. Alcalay R.N., Caccappolo E., Mejia-Santana H., Tang M., Rosado L., Orbe Reilly M., Ruiz D., Ross B., Verbitsky M., Kisselev S., et al. . 2012. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology. 78:1434–1440 10.1212/WNL.0b013e318253d54b - DOI - PMC - PubMed
    1. Alzheimer’s Association and Centers for Disease Control and Prevention. 2013. The Healthy Brain Initiative: The Public Health Road Map for State and National Partnerships, 2013–2018. Alzheimer’s Association, Chicago, IL. Available at: http://www.alz.org/publichealth/downloads/2013-RoadMap.pdf (accessed April 15, 2015).
    1. Beach T.G., Adler C.H., Dugger B.N., Serrano G., Hidalgo J., Henry-Watson J., Shill H.A., Sue L.I., Sabbagh M.N., and Akiyama H.. Arizona Parkinson’s Disease Consortium. 2013. Submandibular gland biopsy for the diagnosis of Parkinson disease. J. Neuropathol. Exp. Neurol. 72:130–136 10.1097/NEN.0b013e3182805c72 - DOI - PMC - PubMed

Publication types